谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design

Shinya Fujiki,Kenichi Iijima,Masaaki Okabe,Shinichi Niwano,Kenichi Tsujita,Shigeto Naito,Kenji Ando,Kengo Kusano,Ritsushi Kato,Junichi Nitta,Tetsuji Miura,Takeshi Mitsuhashi,Kazuomi Kario,Yusuke Kondo,Masaki Ieda,Nobuhisa Hagiwara,Toyoaki Murohara,Kazuyoshi Takahashi,Hirofumi Tomita,Yasuchika Takeishi,Toshihisa Anzai,Wataru Shimizu,Masafumi Watanabe,Yoshihiro Morino,Takeshi Kato,Hiroshi Tada,Yoshihisa Nakagawa,Masafumi Yano,Koji Maemura,Takeshi Kimura,Hisako Yoshida,Keiko Ota,Takahiro Tanaka,Nobutaka Kitamura,Koichi Node,Yoshifusa Aizawa,Ippei Shimizu,Daisuke Izumi,Kazuyuki Ozaki,Tohru Minamino,Masaaki Okabe

DIABETES THERAPY（2020）

引用 8|浏览14
暂无评分
关键词
Arrhythmia, Empagliflozin (EMPA), Implantable cardioverter-defibrillator (ICD), Ketone bodies, Sympathetic nerve activity, Type 2 diabetes (T2DM)
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要